Safety and Efficacy of Pioglitazone as an Anti-inflammatory for the Treatment of Cystic Fibrosis (CF) Lung Disease
Status:
Completed
Trial end date:
2007-04-01
Target enrollment:
Participant gender:
Summary
Study Hypothesis: Pioglitazone may decrease inflammation in cystic fibrosis lung disease.
Primary outcomes: Markers of inflammation (neutrophils, elastase, cytokines and bacteria)will
be measured in induced sputum specimens before and after a 4 week treatment period with
pioglitazone in clinically stable CF patients.
Phase:
N/A
Details
Lead Sponsor:
University Hospitals Cleveland Medical Center
Collaborators:
Cystic Fibrosis Foundation Cystic Fibrosis Foundation Therapeutics